Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05342675 · ClinicalTrials.gov registry record · NA

Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy

A NA study of Lung Cancer and Pneumothorax, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
54
Enrollment target
2
Study locations

NCT05342675: Completed NA study of Lung Cancer and Pneumothorax, sponsored by University of California, San Francisco.

NCT05342675 is a NA study of Lung Cancer and Pneumothorax that has completed, run by University of California, San Francisco. The registered enrollment target is 54 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05342675, a NA study of Lung Cancer and Pneumothorax, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
54 participants
Enrollment target
2
Study locations

Study Summary

Pneumothorax is the most common complication after CT-guided lung biopsy, and several techniques have been proposed to reduce the risk. Among them, rapid rollover is the maneuver to immediately reposition the patient, with biopsy-side down after removal of biopsy needle. It has been theorized that the technique reduces the size of alveoli surrounding the needle tract, leading to airway closure and reduction in the alveolar-to-pleural pressure gradient, thereby preventing pneumothorax. The aim of this study is to evaluate the effectiveness of rapid rollover in reducing the risk of radiographically detectable pneumothorax and the rate of chest tube insertion. Patients undergoing CT-guided lung biopsy for any indication will be recruited and randomized into either rapid rollover group or control group. In the control group, CT guided lung biopsy will be performed per standard protocols; in the rapid rollover group, the biopsy will also be performed per the same protocol with the addition of rapid rollover at the end of the procedure. For both groups, the primary outcome would be new or enlarging pneumothorax detected on post-biopsy radiographs, and the secondary outcome would be the risk of pneumothorax necessitating chest tube insertion, all complications associated with CT guided lung biopsy, time to complication development, and patient experience in each arm.

Primary Outcome

New or enlarging pneumothorax (from intraprocedural CT) which is detectable on post biopsy radiograph. The size of the pneumothorax will be measured in terms of the distance between visceral and parietal pleura. The severity of pneumothorax will be assessed using CTCAE 5.0.

Conditions Studied

Interventions

  • PROCEDURE Rapid Rollover

Study Locations (2)

California

  • Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco
  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2022-09-15
Est. Completion 2024-06-30
Phase NA

What the finished NCT05342675 record still lists

NCT05342675 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Rapid Rollover is the first listed.

NCT05342675 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05342675 about?

NCT05342675 is a clinical study titled "Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy". Pneumothorax is the most common complication after CT-guided lung biopsy, and several techniques have been proposed to reduce the risk. Among them, rapid rollover is the maneuver to immediately reposition the patient, with biopsy-side down after removal of biopsy needle. It has been theorized that t...

What is the current status of trial NCT05342675?

This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2022-09-15. Estimated completion is 2024-06-30.

What conditions does trial NCT05342675 study?

This clinical trial studies the following conditions: Lung Cancer, Pneumothorax.

What interventions are being tested in trial NCT05342675?

The interventions under investigation include: Rapid Rollover (PROCEDURE).

Who is sponsoring clinical trial NCT05342675?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05342675 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05342675's enrollment target sits among peer trials

54 258th of 409 higher than 152 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05342675, the US trial registry maintained by the National Library of Medicine. NCT05342675 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.